Treatment of Lupus Nephritis by Mycophenolate Mofetil
Background/Aims: Mycophenolate mofetil (MMF) has been increasingly used for the treatment of lupus nephritis (LN). The aim of this study was to examine the efficacy and safety of MMF used with low doses of corticosteroids as maintenance therapy in patients with LN. Methods: The study covered 35 pati...
Gespeichert in:
| Veröffentlicht in: | Kidney & blood pressure research 2010-01, Vol.33 (4), p.297-303 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 303 |
|---|---|
| container_issue | 4 |
| container_start_page | 297 |
| container_title | Kidney & blood pressure research |
| container_volume | 33 |
| creator | Rabrenović, Violeta Poskurica, Mileta Kovačević, Zoran Nešić, Vidosava Savin, Marina Mitić, Branka Dimković, Nada Čučković, Čedomir Vujić, Danica Plješa, Steva Peruničić-Peković, Gordana Čurić, Slobodan Mitić, Igor Ratković, Marina Marinković, Jelena Jovanović, Dragan |
| description | Background/Aims: Mycophenolate mofetil (MMF) has been increasingly used for the treatment of lupus nephritis (LN). The aim of this study was to examine the efficacy and safety of MMF used with low doses of corticosteroids as maintenance therapy in patients with LN. Methods: The study covered 35 patients, most of them with proliferative types of LN (5 WHO class III, 26 class IV), while 1 had class V and 3 class VI nephritis. MMF was administered in the dose of 1.5–2 g/24 h and prednisone at 10–20 mg/day. The treatment effects were followed over a 12-month period. Results: After 3 months of therapy significant reduction in proteinuria was achieved (2.1 ± 2.4 g/24 h vs. 1.0 ± 1.0 g/24 h, p < 0.01) and maintained to the end of the study. In parallel, a significant rise in serum albumin, a fall of cholesterol and a significant increase in mean glomerular filtration rate were noted. Complete remission was achieved in 16 patients (45.7%), including all patients in class III and V plus 10 patients in class IV. Not a single adverse effect was observed. Conclusion: MMF combined with low doses of steroids is an effective and safe treatment for the maintenance of stable remission of LN. |
| doi_str_mv | 10.1159/000316321 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_749014029</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>749014029</sourcerecordid><originalsourceid>FETCH-LOGICAL-c367t-8ae42653e605192926726f58f91ae1d44599358aa49a0eda5dd5a4c3aeb187f53</originalsourceid><addsrcrecordid>eNpd0D1PwzAQBmALgWgpDOwIRSyIIeDvxCOq-JJaWMpsucmFpiRxsJ2h_x5DSwcmn-THd-cXoXOCbwkR6g5jzIhklBygMeGUpZhwdvhb45RjJUfoxPt1ZAJjeoxGFEsZ79QYiYUDE1roQmKrZDb0g09eoV-5OtQ-WW6S-aaw_Qo625gAydxWEOrmFB1VpvFwtjsn6P3xYTF9TmdvTy_T-1laMJmFNDfAqRQMJBZEUUVlRmUl8koRA6TkXCjFRG4MVwZDaURZCsMLZmBJ8qwSbIKut317Z78G8EG3tS-gaUwHdvA64yp-FVMV5dU_ubaD6-JyOhNC8DzOiehmiwpnvXdQ6d7VrXEbTbD-SVLvk4z2ctdwWLZQ7uVfdBFcbMGncR_g9mD3_hvzHHQx</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>755548358</pqid></control><display><type>article</type><title>Treatment of Lupus Nephritis by Mycophenolate Mofetil</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><source>EZB Electronic Journals Library</source><creator>Rabrenović, Violeta ; Poskurica, Mileta ; Kovačević, Zoran ; Nešić, Vidosava ; Savin, Marina ; Mitić, Branka ; Dimković, Nada ; Čučković, Čedomir ; Vujić, Danica ; Plješa, Steva ; Peruničić-Peković, Gordana ; Čurić, Slobodan ; Mitić, Igor ; Ratković, Marina ; Marinković, Jelena ; Jovanović, Dragan</creator><creatorcontrib>Rabrenović, Violeta ; Poskurica, Mileta ; Kovačević, Zoran ; Nešić, Vidosava ; Savin, Marina ; Mitić, Branka ; Dimković, Nada ; Čučković, Čedomir ; Vujić, Danica ; Plješa, Steva ; Peruničić-Peković, Gordana ; Čurić, Slobodan ; Mitić, Igor ; Ratković, Marina ; Marinković, Jelena ; Jovanović, Dragan</creatorcontrib><description>Background/Aims: Mycophenolate mofetil (MMF) has been increasingly used for the treatment of lupus nephritis (LN). The aim of this study was to examine the efficacy and safety of MMF used with low doses of corticosteroids as maintenance therapy in patients with LN. Methods: The study covered 35 patients, most of them with proliferative types of LN (5 WHO class III, 26 class IV), while 1 had class V and 3 class VI nephritis. MMF was administered in the dose of 1.5–2 g/24 h and prednisone at 10–20 mg/day. The treatment effects were followed over a 12-month period. Results: After 3 months of therapy significant reduction in proteinuria was achieved (2.1 ± 2.4 g/24 h vs. 1.0 ± 1.0 g/24 h, p < 0.01) and maintained to the end of the study. In parallel, a significant rise in serum albumin, a fall of cholesterol and a significant increase in mean glomerular filtration rate were noted. Complete remission was achieved in 16 patients (45.7%), including all patients in class III and V plus 10 patients in class IV. Not a single adverse effect was observed. Conclusion: MMF combined with low doses of steroids is an effective and safe treatment for the maintenance of stable remission of LN.</description><identifier>ISSN: 1420-4096</identifier><identifier>EISSN: 1423-0143</identifier><identifier>DOI: 10.1159/000316321</identifier><identifier>PMID: 20664209</identifier><identifier>CODEN: RPBIEL</identifier><language>eng</language><publisher>Basel, Switzerland: S. Karger AG</publisher><subject>Adrenal Cortex Hormones - administration & dosage ; Adrenal Cortex Hormones - adverse effects ; Adult ; Drug Therapy, Combination ; Female ; Follow-Up Studies ; Humans ; Immunosuppressive Agents - administration & dosage ; Immunosuppressive Agents - adverse effects ; Lupus Nephritis - drug therapy ; Male ; Middle Aged ; Mycophenolic Acid - administration & dosage ; Mycophenolic Acid - adverse effects ; Mycophenolic Acid - analogs & derivatives ; Original Paper ; Prospective Studies ; Remission Induction</subject><ispartof>Kidney & blood pressure research, 2010-01, Vol.33 (4), p.297-303</ispartof><rights>2010 S. Karger AG, Basel</rights><rights>Copyright (c) 2010 S. Karger AG, Basel.</rights><rights>Copyright (c) 2010 S. Karger AG, Basel</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c367t-8ae42653e605192926726f58f91ae1d44599358aa49a0eda5dd5a4c3aeb187f53</citedby><cites>FETCH-LOGICAL-c367t-8ae42653e605192926726f58f91ae1d44599358aa49a0eda5dd5a4c3aeb187f53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20664209$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rabrenović, Violeta</creatorcontrib><creatorcontrib>Poskurica, Mileta</creatorcontrib><creatorcontrib>Kovačević, Zoran</creatorcontrib><creatorcontrib>Nešić, Vidosava</creatorcontrib><creatorcontrib>Savin, Marina</creatorcontrib><creatorcontrib>Mitić, Branka</creatorcontrib><creatorcontrib>Dimković, Nada</creatorcontrib><creatorcontrib>Čučković, Čedomir</creatorcontrib><creatorcontrib>Vujić, Danica</creatorcontrib><creatorcontrib>Plješa, Steva</creatorcontrib><creatorcontrib>Peruničić-Peković, Gordana</creatorcontrib><creatorcontrib>Čurić, Slobodan</creatorcontrib><creatorcontrib>Mitić, Igor</creatorcontrib><creatorcontrib>Ratković, Marina</creatorcontrib><creatorcontrib>Marinković, Jelena</creatorcontrib><creatorcontrib>Jovanović, Dragan</creatorcontrib><title>Treatment of Lupus Nephritis by Mycophenolate Mofetil</title><title>Kidney & blood pressure research</title><addtitle>Kidney Blood Press Res</addtitle><description>Background/Aims: Mycophenolate mofetil (MMF) has been increasingly used for the treatment of lupus nephritis (LN). The aim of this study was to examine the efficacy and safety of MMF used with low doses of corticosteroids as maintenance therapy in patients with LN. Methods: The study covered 35 patients, most of them with proliferative types of LN (5 WHO class III, 26 class IV), while 1 had class V and 3 class VI nephritis. MMF was administered in the dose of 1.5–2 g/24 h and prednisone at 10–20 mg/day. The treatment effects were followed over a 12-month period. Results: After 3 months of therapy significant reduction in proteinuria was achieved (2.1 ± 2.4 g/24 h vs. 1.0 ± 1.0 g/24 h, p < 0.01) and maintained to the end of the study. In parallel, a significant rise in serum albumin, a fall of cholesterol and a significant increase in mean glomerular filtration rate were noted. Complete remission was achieved in 16 patients (45.7%), including all patients in class III and V plus 10 patients in class IV. Not a single adverse effect was observed. Conclusion: MMF combined with low doses of steroids is an effective and safe treatment for the maintenance of stable remission of LN.</description><subject>Adrenal Cortex Hormones - administration & dosage</subject><subject>Adrenal Cortex Hormones - adverse effects</subject><subject>Adult</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Immunosuppressive Agents - administration & dosage</subject><subject>Immunosuppressive Agents - adverse effects</subject><subject>Lupus Nephritis - drug therapy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Mycophenolic Acid - administration & dosage</subject><subject>Mycophenolic Acid - adverse effects</subject><subject>Mycophenolic Acid - analogs & derivatives</subject><subject>Original Paper</subject><subject>Prospective Studies</subject><subject>Remission Induction</subject><issn>1420-4096</issn><issn>1423-0143</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpd0D1PwzAQBmALgWgpDOwIRSyIIeDvxCOq-JJaWMpsucmFpiRxsJ2h_x5DSwcmn-THd-cXoXOCbwkR6g5jzIhklBygMeGUpZhwdvhb45RjJUfoxPt1ZAJjeoxGFEsZ79QYiYUDE1roQmKrZDb0g09eoV-5OtQ-WW6S-aaw_Qo625gAydxWEOrmFB1VpvFwtjsn6P3xYTF9TmdvTy_T-1laMJmFNDfAqRQMJBZEUUVlRmUl8koRA6TkXCjFRG4MVwZDaURZCsMLZmBJ8qwSbIKut317Z78G8EG3tS-gaUwHdvA64yp-FVMV5dU_ubaD6-JyOhNC8DzOiehmiwpnvXdQ6d7VrXEbTbD-SVLvk4z2ctdwWLZQ7uVfdBFcbMGncR_g9mD3_hvzHHQx</recordid><startdate>20100101</startdate><enddate>20100101</enddate><creator>Rabrenović, Violeta</creator><creator>Poskurica, Mileta</creator><creator>Kovačević, Zoran</creator><creator>Nešić, Vidosava</creator><creator>Savin, Marina</creator><creator>Mitić, Branka</creator><creator>Dimković, Nada</creator><creator>Čučković, Čedomir</creator><creator>Vujić, Danica</creator><creator>Plješa, Steva</creator><creator>Peruničić-Peković, Gordana</creator><creator>Čurić, Slobodan</creator><creator>Mitić, Igor</creator><creator>Ratković, Marina</creator><creator>Marinković, Jelena</creator><creator>Jovanović, Dragan</creator><general>S. Karger AG</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7T7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>S0X</scope><scope>7X8</scope></search><sort><creationdate>20100101</creationdate><title>Treatment of Lupus Nephritis by Mycophenolate Mofetil</title><author>Rabrenović, Violeta ; Poskurica, Mileta ; Kovačević, Zoran ; Nešić, Vidosava ; Savin, Marina ; Mitić, Branka ; Dimković, Nada ; Čučković, Čedomir ; Vujić, Danica ; Plješa, Steva ; Peruničić-Peković, Gordana ; Čurić, Slobodan ; Mitić, Igor ; Ratković, Marina ; Marinković, Jelena ; Jovanović, Dragan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c367t-8ae42653e605192926726f58f91ae1d44599358aa49a0eda5dd5a4c3aeb187f53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Adrenal Cortex Hormones - administration & dosage</topic><topic>Adrenal Cortex Hormones - adverse effects</topic><topic>Adult</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Immunosuppressive Agents - administration & dosage</topic><topic>Immunosuppressive Agents - adverse effects</topic><topic>Lupus Nephritis - drug therapy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Mycophenolic Acid - administration & dosage</topic><topic>Mycophenolic Acid - adverse effects</topic><topic>Mycophenolic Acid - analogs & derivatives</topic><topic>Original Paper</topic><topic>Prospective Studies</topic><topic>Remission Induction</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rabrenović, Violeta</creatorcontrib><creatorcontrib>Poskurica, Mileta</creatorcontrib><creatorcontrib>Kovačević, Zoran</creatorcontrib><creatorcontrib>Nešić, Vidosava</creatorcontrib><creatorcontrib>Savin, Marina</creatorcontrib><creatorcontrib>Mitić, Branka</creatorcontrib><creatorcontrib>Dimković, Nada</creatorcontrib><creatorcontrib>Čučković, Čedomir</creatorcontrib><creatorcontrib>Vujić, Danica</creatorcontrib><creatorcontrib>Plješa, Steva</creatorcontrib><creatorcontrib>Peruničić-Peković, Gordana</creatorcontrib><creatorcontrib>Čurić, Slobodan</creatorcontrib><creatorcontrib>Mitić, Igor</creatorcontrib><creatorcontrib>Ratković, Marina</creatorcontrib><creatorcontrib>Marinković, Jelena</creatorcontrib><creatorcontrib>Jovanović, Dragan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Virology and AIDS Abstracts</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Databases</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><jtitle>Kidney & blood pressure research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rabrenović, Violeta</au><au>Poskurica, Mileta</au><au>Kovačević, Zoran</au><au>Nešić, Vidosava</au><au>Savin, Marina</au><au>Mitić, Branka</au><au>Dimković, Nada</au><au>Čučković, Čedomir</au><au>Vujić, Danica</au><au>Plješa, Steva</au><au>Peruničić-Peković, Gordana</au><au>Čurić, Slobodan</au><au>Mitić, Igor</au><au>Ratković, Marina</au><au>Marinković, Jelena</au><au>Jovanović, Dragan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment of Lupus Nephritis by Mycophenolate Mofetil</atitle><jtitle>Kidney & blood pressure research</jtitle><addtitle>Kidney Blood Press Res</addtitle><date>2010-01-01</date><risdate>2010</risdate><volume>33</volume><issue>4</issue><spage>297</spage><epage>303</epage><pages>297-303</pages><issn>1420-4096</issn><eissn>1423-0143</eissn><coden>RPBIEL</coden><abstract>Background/Aims: Mycophenolate mofetil (MMF) has been increasingly used for the treatment of lupus nephritis (LN). The aim of this study was to examine the efficacy and safety of MMF used with low doses of corticosteroids as maintenance therapy in patients with LN. Methods: The study covered 35 patients, most of them with proliferative types of LN (5 WHO class III, 26 class IV), while 1 had class V and 3 class VI nephritis. MMF was administered in the dose of 1.5–2 g/24 h and prednisone at 10–20 mg/day. The treatment effects were followed over a 12-month period. Results: After 3 months of therapy significant reduction in proteinuria was achieved (2.1 ± 2.4 g/24 h vs. 1.0 ± 1.0 g/24 h, p < 0.01) and maintained to the end of the study. In parallel, a significant rise in serum albumin, a fall of cholesterol and a significant increase in mean glomerular filtration rate were noted. Complete remission was achieved in 16 patients (45.7%), including all patients in class III and V plus 10 patients in class IV. Not a single adverse effect was observed. Conclusion: MMF combined with low doses of steroids is an effective and safe treatment for the maintenance of stable remission of LN.</abstract><cop>Basel, Switzerland</cop><pub>S. Karger AG</pub><pmid>20664209</pmid><doi>10.1159/000316321</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1420-4096 |
| ispartof | Kidney & blood pressure research, 2010-01, Vol.33 (4), p.297-303 |
| issn | 1420-4096 1423-0143 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_749014029 |
| source | MEDLINE; Alma/SFX Local Collection; EZB Electronic Journals Library |
| subjects | Adrenal Cortex Hormones - administration & dosage Adrenal Cortex Hormones - adverse effects Adult Drug Therapy, Combination Female Follow-Up Studies Humans Immunosuppressive Agents - administration & dosage Immunosuppressive Agents - adverse effects Lupus Nephritis - drug therapy Male Middle Aged Mycophenolic Acid - administration & dosage Mycophenolic Acid - adverse effects Mycophenolic Acid - analogs & derivatives Original Paper Prospective Studies Remission Induction |
| title | Treatment of Lupus Nephritis by Mycophenolate Mofetil |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T17%3A48%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20of%20Lupus%20Nephritis%20by%20Mycophenolate%20Mofetil&rft.jtitle=Kidney%20&%20blood%20pressure%20research&rft.au=Rabrenovi%C4%87,%20Violeta&rft.date=2010-01-01&rft.volume=33&rft.issue=4&rft.spage=297&rft.epage=303&rft.pages=297-303&rft.issn=1420-4096&rft.eissn=1423-0143&rft.coden=RPBIEL&rft_id=info:doi/10.1159/000316321&rft_dat=%3Cproquest_cross%3E749014029%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=755548358&rft_id=info:pmid/20664209&rfr_iscdi=true |